摘要
目的研究Ⅰb2-Ⅱb宫颈癌术前新辅助化疗(neoadjuvant chemotherapy,NACT)的疗效。方法选择2010年1月—2012年6月收治的Ⅰb2-Ⅱb期宫颈癌患者47例,采用紫杉醇联合顺铂(TP)化疗方案:紫杉醇150～175mg/m2静脉滴注1 d,顺铂50 mg/m2分2 d静脉滴注,化疗后均行腹腔镜广泛全子宫切除加盆腔淋巴结清扫术。结果本组47例巨块型子宫颈癌应用辅助化疗治疗,有效率(CR+PR)82.98%(39/47),其中12例Ⅰb2期患者宫颈肿物完全消失,效果显著。不同期别宫颈癌患者化疗后肿瘤均较化疗前明显缩小,差异有统计学意义(P<0.05)。结论术前采用NACT可使肿瘤缩小,提高症状改善率和手术切除率,为争取早中期宫颈癌根治提供条件。
Objective To study the clinical efficacy of preoperative neoedjuvant chemotherapy in cervical carcinoma of stage Ⅰb2-Ⅱb. Methods From January 2010 to June 2012, 47 patients with cervical carcinoma of stage Ⅰb2-Ⅱb were treated hy TP regiment （paclitaxel plus cisplatin）, in which paclitaxal was administered intravenously in a dose of 150 - 175mg/m2 and cisplatin 50mg/m2. All patients underwent laparoscopie radical hysterectomy with pelvic lymph node dis- section. Results For these 47 patients of balky cervical cancer,the effective rate of adjuvant chemotherapy（CR ＋ PR） was 82.98% （39/47）, d which cervical tumor completely disappeared in 12 patients of stage Ⅰb2,and the effect was sig- nificant. Tumor in different stages shrunk significantly after chemotherapy, and there was significantly statistical difference （ P 〈 0.01 ）. Conclusions Preoperative neoedjuvant chemotherapy can create tumor - shrinking, improve the rate of symp- tom improvement and surgical resection, which provides conditions for curing cervical cancer in early or middle stage.
出处
《社区医学杂志》
2013年第12期7-9,共3页
Journal Of Community Medicine
关键词
宫颈癌
新辅助化疗
临床分析
cervical cancer
neoadjuvant chemotherapy
cllnlcal ana]ysis
